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CLEC16A variation has been associated
with multiple autoimmune disorders, but
how this gene contributes to disease
susceptibility is unknown. Kissler and
colleagues show that Clec16a, owing to
its role in autophagy, impacts the function
of thymic epithelial cells and thereby
alters T cell selection and the risk of
autoimmunity.
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CLEC16A variation has been associated with multi-
ple immune-mediated diseases, including type 1
diabetes, multiple sclerosis, systemic lupus ery-
thematosus, celiac disease, Crohn’s disease, Addi-
son’s disease, primary biliary cirrhosis, rheumatoid
arthritis, juvenile idiopathic arthritis, and alopecia
areata. Despite strong genetic evidence implicating
CLEC16A in autoimmunity, this gene’s broad associ-
ation with disease remains unexplained. We gener-
atedClec16a knock-down (KD) mice in the nonobese
diabetic (NOD) model for type 1 diabetes and found
that Clec16a silencing protected against autoimmu-
nity. Disease protection was attributable to T cell
hyporeactivity, which was secondary to changes in
thymic epithelial cell (TEC) stimuli that drive thymo-
cyte selection. Our data indicate that T cell selection
and reactivity were impacted by Clec16a variation in
thymic epithelium owing to Clec16a’s role in TEC
autophagy. These findings provide a functional link
between human CLEC16A variation and the immune
dysregulation that underlies the risk of autoimmunity.
INTRODUCTION
Genome-wide association studies (GWASs) have helped identify
numerous gene variants that contribute to the risk of autoimmu-
nity. Despite the vast catalog of causal candidate genes gener-
ated by GWAS, the functional contribution to disease of most
autoimmunity-associated gene variations remains to be defined
(Hu and Daly, 2012). Notably, several genetic loci stand out for
having been very broadly associated with autoimmunity. Among
these, variations within CLEC16A at chromosomal position
16p13 have been associated with no less than ten diseases,
including type 1 diabetes, multiple sclerosis, systemic lupus
erythematosus, celiac disease, Crohn’s disease, Addison’s dis-
ease, primary biliary cirrhosis, rheumatoid arthritis, juvenile idio-
pathic arthritis, and alopecia areata (Dubois et al., 2010; Gateva942 Immunity 42, 942–952, May 19, 2015 ª2015 Elsevier Inc.et al., 2009; Hakonarson et al., 2007; Hirschfield et al., 2012;
IMSGC, 2009; Jagielska et al., 2012; Ma´rquez et al., 2009; Mar-
tı´nez et al., 2010; Skinningsrud et al., 2008; Skinningsrud et al.,
2010; Todd et al., 2007; WTCCC, 2007). The association of
CLEC16A variation with multiple autoimmune disorders thus im-
plicates this gene in an as-yet undefined but likely fundamental
aspect of immune regulation.
CLEC16A encodes a large protein of 1,053 amino acids that
contains several putative functional domains, including a C-
type lectin domain, which led to its classification as C-type lectin
domain family 16A (Berge et al., 2013). At the timeCLEC16Awas
associated first with type 1 diabetes (Hakonarson et al., 2007;
Todd et al., 2007;WTCCC, 2007) and thenwithmultiple sclerosis
(IMSGC, 2009), this gene formerly known as KIAA0350 had
neither been classified nor was anything known of its function.
The first data relating to CLEC16A’s cellular function came
from studies of its Drosophila ortholog, termed Ema, that was
shown to participate in endosomal maturation (Kim et al.,
2010) and autophagy (Kim et al., 2012). A role in autophagy
was recently confirmed in mouse, where b cell-specific deletion
of Clec16a impaired mitophagy (Soleimanpour et al., 2014). In
their study of mice with Clec16a-deficient b cells, Soleimanpour
and colleagues suggested that variation in CLEC16A function in
the pancreas might be causal for this gene’s association with
type 1 diabetes. These investigators postulated that a defect in
insulin secretion secondary to disrupted autophagy would pre-
dispose b cells to the autoimmune destruction that causes
type 1 diabetes. However, this hypothesis does not provide an
explanation for CLEC16A’s association with a broad array of im-
mune-mediated diseases (Dubois et al., 2010; Gateva et al.,
2009; Hakonarson et al., 2007; Hirschfield et al., 2012; IMSGC,
2009; Jagielska et al., 2012; Ma´rquez et al., 2009; Martı´nez
et al., 2010; Skinningsrud et al., 2008; Skinningsrud et al.,
2010; Todd et al., 2007; WTCCC, 2007). The functional link be-
tween CLEC16A variation and autoimmunity therefore remains
to be convincingly explained.
The data presented herein indicate that Clec16a variation im-
pacts thymic selection, owing to a role in thymic epithelial cell
autophagy, thus implicating CLEC16A in a fundamental aspect
of immune tolerance. Our findings thereby provide a functional
link between CLEC16A variation and the immune dysregulation
that broadly underlies the risk of autoimmune disease.
Figure 1. Clec16a KD Prevents Autoimmunity by Reducing the Pathogenicity of T Cells
(A) Spontaneous diabetes frequency in cohorts of WT (n = 50) and Clec16a KD (KD, n = 42) NOD mice, p < 0.0001.
(B) Insulitis inWT and KDmice at 4, 6, 8, and 10weeks of age. n = 2–5mice (150–500 islets) per group. Islets were scored as free of insulitis, or as havingmoderate
or severe infiltration, as shown in representative images.
(C) Cyclophosphamide (CY) diabetes in WT (n = 10) and KD (n = 13) mice, p = 0.0035.
(D) CY diabetes in NOD.SCID mice reconstituted with WT (n = 16) or KD (n = 18) splenocytes, p = 0.0002.
(E) Diabetes frequency in WT NOD.SCID (n = 13) or Clec16a KD NOD.SCID (n = 14) mice reconstituted with WT splenocytes, p = 0.36.
(F) CY diabetes in NOD.SCID mice reconstituted with T and B cells, respectively, in the following combinations: WT/WT (n = 7), WT/KD (n = 5), KD/WT
(n = 5), KD/KD (n = 4), p = 0.0046 for WT T cell groups versus KD T cell groups using Fisher’s exact test.RESULTS
Clec16a Silencing Diminishes the Diabetogenicity of
NOD T Cells
To investigate CLEC16A function in autoimmunity, particularly in
relation to autoimmune diabetes, we generated Clec16a KD
mice in the NOD model for type 1 diabetes (Anderson and Blue-
stone, 2005) (Figure S1). Transgenic mice developed normally
and were born with the expected Mendelian frequency. No
changes in the gross distribution and number of immune cell
populations were detected. Strikingly, Clec16a KD NOD mice
were almost completely protected from spontaneous autoim-
mune diabetes (Figures 1A and 1B). Even when diabetes onset
was accelerated using cyclophosphamide (Harada and Makino,
1984), Clec16a silencing afforded protection (Figure 1C). To test
whether this protection was conveyed by changes in lymphocyte
function, we transferred splenocytes fromClec16a KD orWT an-
imals into immunodeficient NOD.SCID mice. Recipients of
Clec16a KD, but not WT, cells were largely resistant to cyclo-
phosphamide-accelerated diabetes (Figure 1D). In contrast,
transfer of WT splenocytes to Clec16a KD NOD.SCID mice
restored full disease susceptibility, indicating that protection
derived from changes in immune function (Figure 1E) and not
from a pancreas-intrinsic resistance to autoimmune damage.
Having established that loss of Clec16a renders NOD lympho-
cytes less diabetogenic, we next sought to localize this effect
to a specific cell population. We purified T and B lymphocytesfrom WT and Clec16a KD mice and reconstituted NOD.SCID
animals with all four possible combinations of cells. Disease pro-
tection was confined to groups that received transgenic T cells,
irrespective of the genotype of co-transferred B cells (Figure 1F).
We concluded that Clec16a KD reduces the pathogenicity of
NOD T cells.
Clec16a Silencing Causes CD4+ T Cell Hyporeactivity
We proceeded to characterize T cell function in more detail
in vitro. Stimulation of polyclonal CD4+ T cells from WT and
Clec16a KD NOD mice revealed that Clec16a silencing caused
T cells to be hyporesponsive to T cell receptor (TCR) stimulation,
but not to PMA and ionomycin, which provide mitogenic
stimuli that circumvent TCR ligation (Figures 2A and 2B, and
Figure S2). T cell hyporeactivity was confined to CD4+ cells,
because CD8+ cells were not impaired in their response to
TCR ligation (Figure S2). Because hyporesponsiveness could
be overcome by mitogens that bypass proximal TCR signaling,
we measured phosphorylation events immediately downstream
of the TCR complex. We found that CD4+ T cells from Clec16a
KD mice responded poorly to TCR ligation, as measured by
diminished phosphorylation of the signaling molecules ZAP-70
and PLC-g and ERK1/2 (Figure 2C). We then tested whether
antigen-specific stimulation was similarly impaired by Clec16a
KD. The response to BDC2.5 mimotope peptide stimulation
of T cells from Clec16a KD BDC2.5 TCR transgenic mice was
reduced compared to WT BDC2.5 T cells. In this setting,Immunity 42, 942–952, May 19, 2015 ª2015 Elsevier Inc. 943
Figure 2. Clec16a KD Causes T Cell Hyporeactivity
(A and B) Proliferation of CD4 T cells in response to CD3 antibody (A, left panel), CD3/CD28 antibody-coated beads (A, right panel) or PMA and ionomycin (B).
(C) Western blot measurements of ZAP-70, PLC-g, and ERK1/2 phosphorylation in WT or KD CD4 T cells stimulated with cross-linked CD3 antibody for the
indicated length of time (in min).
(D) Proliferation of WT or KD TCR transgenic BDC2.5 CD4 T cells in response to BDC2.5 mimotope peptide (left panel), CD3 antibody (1 mg / ml, middle panel), or
PMA and ionomycin (right panel).
(E) Suppression of WT CD4 T cell proliferation byWT or KD CD4+CD25+ Treg cells. Results showmean ± SEM of triplicate measurements and are representative
of two to four experiments. **p < 0.01.
See also Figure S2.hyporesponsiveness was again overcome by PMA and ionomy-
cin stimulation, but not by CD3 antibody stimulation (Figure 2D).
Of note, the suppressive capacity of Clec16a KD regulatory T
(Treg) cells remained comparable to that of WT cells (Figure 2E),
possibly because Treg cell function is less sensitive to changes
in TCR signal strength (Plesa et al., 2012). Together, these results
indicate thatClec16a KD affects TCR signaling, without however
causing complete CD4+ T cell dysfunction.
The Effects of Clec16a Silencing Are Not T Cell Intrinsic
For initial comparisons, T cells had been purified by magnetic
separation. Because expression of the lentiviral transgene is var-
iegated, only 70%–75% of T lymphocytes in Clec16a KD mice
express the transgene, which includes GFP. To more carefully
characterize transgene-expressing cells, we sorted GFP+ and
GFP T cells from Clec16a KD mice by flow cytometry. Both
T cell populations were impaired in their proliferative response
(Figure 3A), suggesting that hyporeactivity was not caused by
T cell-intrinsic effects of gene silencing. To test whether the ef-
fect of Clec16a KD is instead conveyed to T cells during thymic
selection, we generated bone-marrow chimeric mice. The reac-
tivity of Clec16a KD T cells that developed in interaction with WT
TECs in chimeric hosts was indistinguishable from that of WT
T cells (Figure 3B). Critically, irradiated NOD mice reconstituted
withClec16aKDbone-marrowwere not protected fromdiabetes
(Figure 3C), while irradiated Clec16a KD mice reconstituted with
WT bone-marrow remained diabetes resistant (Figure 3D),
demonstrating that disease protection was not conveyed by944 Immunity 42, 942–952, May 19, 2015 ª2015 Elsevier Inc.Clec16a silencing in hematopoietic cells. Transplantation of fetal
WT or Clec16a KD thymus into athymic WT NOD mice showed
that protection from diabetes derived instead from Clec16a KD
in thymic epithelium (Figure 3E). Clec16a KD has been reported
to impair insulin release from b cells (Soleimanpour et al., 2014).
We therefore investigated whether limited availability of this self-
antigen played a role disease protection. However, Clec16a KD
mice secreted insulin and regulated their blood glucose in a
manner indistinguishable from WT animals after intraperitoneal
glucose challenge (Figure S3). The total pancreatic insulin con-
tent was also unaffected by Clec16a KD (Figure S3). Presenta-
tion of b cell antigen in the pancreatic lymph node (PLN) is critical
for the priming of diabetogenic T cells (Ho¨glund et al., 1999). To
test whether antigen presentation was compromised in the PLN
of Clec16a KD mice, we transferred BDC2.5 TCR transgenic
T cells into WT or Clec16a KD animals. We measured robust
BDC2.5 T cell proliferation in the PLNs of both Clec16a KD and
WT recipients (Figure S3). We conclude that presentation of b
cell antigen in peripheral tissue is not affected by Clec16a KD
and that the protective effect of Clec16a silencing originates in
the thymus.
Clec16a Silencing in Thymic Epithelium Modifies T Cell
Selection
To confirm that T cell hyporeactivity was imparted during thymic
development, we tested the reactivity of Clec16a KD thymo-
cytes. CD4 single-positive (SP) thymocytes from Clec16a KD
mice were hyporeactive following in vitro stimulation (Figure 4A).
Figure 3. The Effect of Clec16a Silencing Is
Not T Cell-Intrinsic
(A) Proliferation of GFP+ and GFP Clec16a KD
and WT CD4+ T cells stimulated with anti-CD3
antibody.
(B) Proliferation of FACS-sorted CD4+ T cells from
WT or KD mice (left panel) or from WT bone-
marrow (BM) chimeric mice reconstituted with WT
or KD BM (right panel) stimulated with anti-CD3/
anti-CD28 coated beads.
(C) CY diabetes in WT BM chimeric mice recon-
stituted with WT (n = 6) or KD (n = 4) BM.
(D) CY diabetes in Clec16a KD BM chimeric mice
reconstituted with WT (n = 10) or KD (n = 10) BM,
p = 0.14.
(E) Diabetes frequency in NOD mice thymectom-
ized at 4 weeks of age and subsequently trans-
planted with fetal thymus (E14) from Clec16a KD
(KD3 n = 10, KD5 n = 10) or WT (n = 7) embryos in
conjunction with WT bone-marrow after irradia-
tion, WT versus KD, p = 0.0132. No difference was
observed in either the size of thymuses post-
transplantation or the frequency of T cells in
transplanted mice at the time of diabetes onset
(data not shown).In contrast, Clec16a KD did not diminish the reactivity of double-
positive (DP) thymocytes. In vivo, CD3 antibody caused the dele-
tion of a comparable proportion of DP cells in Clec16a KD and
WT animals (Figure 4B). In vitro, differentiation of DP thymocytes
into CD4SP cells using antibody stimulation (Cibotti et al., 1997)
induced similar responses in WT and KD cells (Figure S4). These
results suggest that hyporeactivity is acquired during thymic se-
lection, in the transition from the DP to the CD4SP maturation
stage.
Although we detected no evidence for altered TCR Vb-chain
selection (Figure 5A), we observed a striking change in the
relative frequency of transgenic thymocytes during selection
(Figures 5B and 5C, and Figure S5). When thymocytes were sub-
divided on the basis of their relative TCR and CD69 expression
(Fu et al., 2009; Hare et al., 1999; Swat et al., 1993), pre-selection
thymocytes (TCRlo/int CD69lo) were over-represented in Clec16a
KD mice, whereas we measured a sharp drop in the frequency
of Clec16a KD thymocytes undergoing selection (TCRint/high
CD69hi). These changes were recapitulated in bone-marrow
chimeric mice, and the phenotype observed in Clec16a KD
mice segregated with the genotype of the irradiated host, and
not with the genotype of transplanted hematopoietic cells (Fig-
ure 5D). These results indicate that Clec16a KD in thymic epithe-
lium, and not in hematopoietic cells, impacts the selection of
developing T cells.
To evaluate the contribution of negative selection to the
decreased frequency of CD69+ thymocytes in Clec16a KD
mice, we measured the expression of Helios, a transcription fac-
tor reported to mark CD4SP cells undergoing deletion (Daley
et al., 2013). We observed a significant increase in Helios+ cells
within the FoxP3CD4SP population (Figure 5E), suggesting that
the loss of CD69+ thymocytes in Clec16a KD mice is caused, at
least in part, by increased negative selection.
We further tracked the fate of developing thymocytes by BrdU
pulse labeling (Figure 5F). The proportion of BrdU+ CD4SP cells
was reduced in transgenic mice at all time points measured afterthe initial BrdU pulse. These results support the notion that
Clec16a KD impairs the transition from DP to CD4SP cells. Sub-
division of BrdU-labeled CD4SP cells into sequential maturation
stages (Daley et al., 2013) defined by their relative expression of
CD24 andCCR7 showed that themost immature (CD24+CCR7)
CD4SP cells were over-represented, while the most mature
(CD24CCR7+) cells were under-represented in transgenic
mice (Figure S5), further indicating that Clec16a KD decreased
the rate of CD4SP cell maturation.
Loss of Clec16a Impairs Thymic Epithelial Cell
Autophagy
Our experiments had shown that the effects of Clec16a KD
originate in non-hematopoietic cells and impact thymic selec-
tion. T cell selection is largely mediated by TECs; we therefore
speculated that Clec16a silencing alters the ability of TECs to
stimulate thymocytes. The Drosophila ortholog of Clec16a was
ascribed a function in autophagy (Kim et al., 2012), and this func-
tion was recently confirmed in mouse (Soleimanpour et al.,
2014). Notably, constitutive autophagy is a distinguishing feature
of thymic epithelium (Nedjic et al., 2008). Furthermore, TEC
autophagy contributes to self-antigen presentation by feeding
peptides derived from cellular proteins into the MHC class II pre-
sentation pathway (Kasai et al., 2009; Nedjic et al., 2008). By
participating in antigen presentation, TEC autophagy was shown
to be critical to thymic selection (Nedjic et al., 2008), providing a
testable link between Clec16a silencing, changes in TEC auto-
phagy, and thymocyte stimulation. After confirming thatClec16a
expression is diminished in TECs from Clec16a KD mice (Fig-
ure 6A), we measured autophagy in thymic epithelium by immu-
nohistochemical staining of the autophagosome-associated
protein LC3 (Kabeya et al., 2000). We observed a modest
increase in the number of autophagosomes in Clec16a KD
mice (Figure 6B), particularly in the cortical TEC (cTEC) compart-
ment that displayed higher levels of autophagy than the thymic
medulla, as reported previously (Kasai et al., 2009; NedjicImmunity 42, 942–952, May 19, 2015 ª2015 Elsevier Inc. 945
Figure 4. Clec16a KD Modifies the Reac-
tivity of CD4SP but Not DP Thymocytes
(A) CD25 upregulation (left) and proliferation (right)
of WT or KD CD4SP cells stimulated in vitro. Error
bars represent mean ± SEM.
(B) Frequency of DP cells in the thymus of WT or
KD mice 48 hr after injection with CD3 antibody.
Results are representative of three experiments.
*p < 0.05, ***p < 0.001.
See also Figure S4.et al., 2008). However, autophagy was decreased overall, as
measured by a reduction of the autophagosome-incorporated
LC3-II isoform (Kabeya et al., 2004) (Figure 6C). These results
are consistent with data reported for Ema mutant Drosophila
showing a modest increase in the number of autophagosomes
but an overall reduction in autophagic flux (Kim et al., 2012). Of
note, decreased autophagy did not affect MHC II expression
on Clec16a KD cTECs. To confirm these findings, we derived a
new cTEC cell line, which we called MJC1. We proceeded to
silence Clec16a or Atg5, a critical component of the autophagy
machinery (Mizushima et al., 1998), in MJC1 cells. Both Clec16a
and Atg5 silencing reduced the conversion of LC3-I into LC3-II
(Figure 6D) and caused the accumulation of p62, a protein
involved in and degraded by autophagy (Bjørkøy et al., 2005)
(Figure 6E), confirming that Clec16a silencing impaired autopha-
gic flux in TECs. To test whetherClec16a’s function in autophagy
is conserved in human, we silenced CLEC16A in HEK293 cells
and in HeLa cells. We found that CLEC16A KD disrupted auto-
phagic flux to a similar extent as ATG5 KD, demonstrating the
involvement of CLEC16A in human autophagy (Figure S6).
Together, these results establish a role for Clec16a in mouse
TEC autophagy and show that this function is conserved in
human.
Clec16a Silencing Modifies the Stimulatory Capacity of
TECs
We next sought to determine whether Clec16a KD directly im-
pacts the ability of TECs to stimulate thymocytes.We speculated
that MJC1 cells, which were derived from cTECs, should have
the capacity to stimulate DP thymocytes in vitro. Although we
found that MJC1 cells express very low amounts of MHC II,
IFN-g treatment caused MHC II upregulation on both control
and Clec16a KD cells (data not shown). Therefore, MJC1 cells
were pre-treated with IFN-g prior to being used for thymocyte
stimulation. Taking into account the obvious caveat that a cell
line could not fully recapitulate thymic selection in all respects,
we sought to ask whetherClec16a silencing in MJC1 cells would
have a detectable effect on thymocyte stimulation, as measured
by co-receptor expression and activation marker upregulation.
Co-culture of CD69lo DP cells with MJC1 cells did indeed cause
a significant proportion of immature thymocytes to upregulate
CD69 and to become CD4SP (Figure 7A and Figure S7). Using
MJC1 cells stably transduced with two different Clec16a shRNA
constructs, we found that Clec16a KD in TECs impaired the pro-
gression of thymocytes from the CD69lo to CD69hi stage (Fig-
ure 7A). Furthermore,Clec16a silencing inMJC1 cells decreased
PD1 upregulation in CD4SP thymocytes that is dependent on946 Immunity 42, 942–952, May 19, 2015 ª2015 Elsevier Inc.TCR stimulation (Keir et al., 2005), and these results mirrored ob-
servations made in vivo (Figure S7). Together, these data sug-
gest that Clec16a KD modifies the stimulatory capacity of
cTECs.
Clec16a Silencing Alters TEC Stimulation of
Thymocytes Owing to Impaired Autophagy
To test whether a direct link exists between changes in TEC
autophagy and thymocyte stimulation, we transduced MJC1
cells with an LC3 transgene that includes the OVA323–339 peptide
and enables autophagy-dependent presentation of this antigen
(Aichinger et al., 2013; Schmid et al., 2007). The OVA peptide
was incorporated within the LC3 protein and is thereby shuttled
to and processed in autophagic vesicles, fromwhich the peptide
gains access to the MHC class II presentation pathway. In this
context, stimulation of OVA323–339 responsive OT-II thymocytes
was impaired by both Atg5 KD and Clec16a KD (Figure 7B). Mu-
tation of the OVA323–339-LC3 construct at a critical cleavage site
(LC3G120A) to prevent its inclusion in autophagosomes (Aichinger
et al., 2013; Schmid et al., 2007) diminished OT-II thymocyte
stimulation by control MJC1 cells, but did not further impair stim-
ulation byAtg5KDorClec16aKDTECs. The effect on thymocyte
stimulation of inhibiting OVA323–339 presentation via autophagy
by mutating the LC3 protein was thus redundant with the effect
of Clec16a silencing that diminishes MJC1 cell autophagy (Fig-
ure S7). These results suggest that Clec16a impacts thymocyte
stimulation owing to its role in autophagy.
DISCUSSION
Collectively, our findings implicate Clec16a in a fundamental
process of immune regulation. Through its role in autophagy,
Clec16a modulates the antigen-presenting function of TECs.
TEC autophagy was shown to contribute to the generation of
MHC class II-peptide complexes that dictate the fate of devel-
oping thymocytes (Kasai et al., 2009; Nedjic et al., 2008). The
role of autophagy in generating MHC class II ligands has been
demonstrated by a number of groups (Brazil et al., 1997; Dengjel
et al., 2005; Paludan et al., 2005; Schmid et al., 2007). Of interest,
Mu¨nz and colleagues reported that LC3, a characteristic compo-
nent of autophagosomes, co-localizes with MHC class II loading
compartments not only in dendritic cells and B cells, but also in
human epithelial cell lines (Schmid et al., 2007). This observation
was extended by Mizuochi and colleagues, who subsequently
showed that autophagy intersects with theMHC class II pathway
in TECs, indicating that autophagosomal cargo gains access to
the MHC class II loading compartment in thymic epithelium.
Figure 5. Clec16a Silencing Impacts Thymic Selection
(A) Frequency of DP or CD4SPCD25 thymocytes that express different TCR Vb chains in the thymus of WT (filled bars, n = 6) or KD3 (open bars, n = 6) mice. Vb5
antibody recognizes both Vb 5.1 and Vb 5.2. Vb8 antibody recognizes both Vb8.1 and Vb8.2. Error bars represent mean ± SEM.
(legend continued on next page)
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Figure 6. Clec16a KD Disrupts TEC Autophagy
(A) Clec16a expression in WT or KD TECs (pooled from four mice per group, triplicate measurements); representative of two experiments. Error bars represent
mean ± SEM.
(B) Autophagosome quantification inWT or KD thymic cortex (shown) andmedulla (not shown) (n = 5mice per group, autophagosomeswere enumerated per area
of a fixed but arbitrary size and data were averaged from five images per mouse). Representative thymus sections used for quantification are shown. Insets show
a magnified area marked by arrows that point to distinct autophagosomes within cells. Error bars represent mean ± SEM.
(C) Quantification of LC3 protein in WT and KD TECs. Results show KD relative to WT and are representative of two experiments.
(D and E) LC3 and p62 quantification inMJC1 cells transducedwith control (ctrl),Clec16a (KD3 and KD5) or Atg5 shRNA. Cells were starved in the presence of the
protease inhibitor E64d (D), or in the presence or absence () of rapamycin (R) or 3-MA (M) that induces and inhibits autophagy, respectively (E). Data shown in (D)
and (E) are representative of three independent experiments.Analysis of the MHC class II ligandome of human B cell lympho-
blastoid cells by mass spectrometry demonstrated that auto-
phagy modifies antigen presentation both by shuttling proteins
from different cellular sources toward the antigen-loading
compartment and by modifying the proteolytic activity of these
cells (Dengjel et al., 2005). How the repertoire of selecting pep-
tides presented by TECs is affected either qualitatively or quan-
titatively by Clec16a silencing remains to be determined, but it is
clear that an impairment of autophagy caused by loss ofClec16a
should significantly alter the MHC class II ligandome.
Our data demonstrate that Clec16a silencing impacts thymic
selection, and these results are consistent with prior experiments
that tested the functional impact of autophagy in the thymus.
Using Atg5-deficient thymic epithelium, Klein and colleagues
showed that the loss of autophagy in TECs altered the selection
of MHC class II restricted T cells (Nedjic et al., 2008). While auto-
phagy was dispensable for the selection of a polyclonal T cell(B and C) Representative flow cytometry data (B) and frequency (C) of thymocyte
(n = 12) mice. Error bars represent mean ± SEM.
(D) Frequency of thymocyte populations as in (C) measured in irradiated WT or K
stitution (n = 6–8 mice per group). Error bars represent mean ± SEM.
(E) Representative flow cytometry data and frequency of CD69+ or Helios+ cells w
mean ± SEM.
(F) Representative flow cytometry data and frequency of BrdU-labeled thymocyte
p = 0.0422 for DP cells and p = 0.0004 for FoxP3CD4SP cells, two-tailed paired t
***p < 0.001. See also Figure S5. Error bars represent mean ± SEM.
948 Immunity 42, 942–952, May 19, 2015 ª2015 Elsevier Inc.repertoire, its absence had a significant effect on individual
TCR specificities. Depending on themodel TCR examined, auto-
phagy had a positive, neutral, or deleterious effect on the selec-
tion of TCR transgenic thymocytes. Consequently, a change in
autophagic flux, as caused by CLEC16A variation, can be pre-
dicted to broadly shape the T cell repertoire and modulate the
risk of autoimmunity. Klein et al. indeed reported that the com-
plete absenceof autophagy in thymic epitheliumcould lead to se-
vere immune-mediated pathology when Atg5-deficient thymus
was transplanted into athymic BALB/c mice. We speculate that
the comparatively mild impairment in autophagy observed in
Clec16a KD mice might have a qualitatively distinct effect on
T cell selection, explaining why Clec16a silencing instead af-
forded protection against autoimmunity in the NOD model of
type 1 diabetes. Of note, epithelial-cell-specific deletion of Atg5
orAtg7causednoobviouspathology in theC57BL/6background
(Sukseree et al., 2012; Sukseree et al., 2013), suggesting that thepopulations distinguished by TCR and CD69 expression in WT (n = 12) and KD
D mice reconstituted with WT or KD bone-marrow (BM) 6 weeks after recon-
ithin the CD4SP population inWT (n = 9) or KD (n = 9) mice. Error bars represent
s following a single injection of BrdU (n = 3 mice per group for each time point),
test. All data are representative of two to four experiments. *p < 0.05, **p < 0.01,
Figure 7. Clec16a Silencing Affects the Stimulatory Capacity of TECs
(A) Frequency of thymocyte subpopulations distinguished by their relative TCR and CD69 expression 4 hr (top panels) and 24 hr (bottom panels) after stimulation
with control or Clec16a KD MJC1 cells. Input cells were WT immature (TCRloCD69lo) thymocytes; representative of three experiments. Error bars represent
mean ± SEM.
(B) Frequency of TCRhi OT-II cells 24 hr after stimulation of immature OT-II thymocytes with control, Clec16a KD or Atg5 KD MJC1 TECs transduced
with OVA323–339-LC3 or OVA323–339-LC3G120A; representative of four experiments. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S7. Error bars represent
mean ± SEM.effect of impaired TEC autophagy on immune tolerance might
differ between genetic backgrounds. Thus, a change in the
contribution of autophagy to TEC antigen presentation does
not merely have a quantitative impact on the MHC II ligandome,
but rather modifies the quality of the selected T cell repertoire in
a difficult-to-predict manner. How the human disease-associ-
ated CLEC16A variants affect T cell reactivity will therefore be a
challenging question to address. Notwithstanding, a role for
CLEC16A in TEC autophagy provides a compelling explanation
for this gene’s associationwith numerous immune-mediated dis-
eases.CLEC16A variation can be anticipated tomodify the reac-
tivity of the T cell repertoire and to fundamentally modulate the
risk of autoimmunity. A role for CLEC16A in the thymus is sup-
ported by a study in human which reported that homozygocity
for the disease-associated variant correlated with altered thymic
expression (Mero et al., 2011).
A recent publication (Soleimanpour et al., 2014) described
that Clec16a participates in autophagy in mouse fibroblasts
and islet cells. These data confirmed earlier findings in
Drosophila (Kim et al., 2012), and are consistent with our
own data showing Clec16a to be involved in TEC autophagy.
Our work further extends these findings by demonstrating that
CLEC16A’s role in autophagy is conserved in human cells. Intheir report, Soleimanpour and colleagues proposed that the
involvement of CLEC16A in type 1 diabetes stems from effects
within pancreatic b cells, but had no disease data in support
of this claim, which is not substantiated by our extensive char-
acterization within the NOD model of autoimmune diabetes.
These authors reported that loss of Clec16a in b cells caused
hyperglycemia as a consequence of defective b cell function.
In this respect, complete Clec16a deficiency would appear to
differ significantly from a partial loss, as neither of the Clec16a
KD mouse lines generated in our laboratory displayed a defec-
tive response to an intraperitoneal glucose tolerance test per-
formed in young pre-diabetic animals. Our transplantation
data instead suggest that the effects of Clec16a silencing on
autoimmunity originate in the thymic epithelium. The hypothesis
that CLEC16A’s effect on disease stems from its role in b cells is
indeed difficult to reconcile with the fact that CLEC16A variation
has been implicated in a wide range of autoimmune disorders
unrelated to the pancreas.
In conclusion, our data highlight the critical function of TEC
autophagy in establishing immune tolerance. TEC autophagy
was previously shown to impact T cell selection in mouse (Nedjic
et al., 2008). By linkingCLEC16A, a gene associated with human
autoimmunity, to this pathway of self-antigen presentation, ourImmunity 42, 942–952, May 19, 2015 ª2015 Elsevier Inc. 949
findings suggest that TEC autophagy plays a similarly pivotal role
in human immune tolerance. CLEC16A’s cellular function re-
mained uncharted until very recently, and how this gene im-
pinges on autoimmunity was therefore unclear. The functional
link between CLEC16A variation and autoimmunity presented
here now provides an explanation for this gene’s broad involve-
ment in human autoimmune disease.
EXPERIMENTAL PROCEDURES
Mice
Clec16a KD mice were generated by lentiviral transgenesis in the NOD mouse
strain as described previously (Kissler et al., 2006). Target sequences for
Clec16a KD were CACCTTGTACGTCATTTCTATA (KD3) and GAGTGTC
CACCTTGTACGTCAT (KD5). WT NOD mice used for comparison in all exper-
iments were bred and housed in the same facility and in the same room as
transgenic mice. NOD BDC2.5 TCR transgenic mice were purchased from
Jackson Laboratories, and bred with Clec16a KD mice to generate the NOD
BDC2.5/Clec16a KD line. OT-II TCRa/mice were kindly provided by T. Ser-
wold. All experimental procedures in animals were approved by the Regional
Government of Lower Franconia or by the Institutional Animal Care and Use
Committee, for experiments performed at the University of Wurzburg and at
the Joslin Diabetes Center, respectively.
Diabetes Frequency Studies
Onset of diabetes was monitored by weekly (for spontaneous disease) or
thrice-weekly (for cyclophosphamide studies and cell transplantation studies)
measurements of glycosuria using Diastix (Bayer).
Bone Marrow Chimeras
Irradiated NOD.SCIDmice (250 rad) or NODmice (900 rad) were injected intra-
venously with lineage-depleted bone-marrow cells (3–5 3 105 / mouse).
Thymic Transplantation
Thymectomized NOD WT mice were purchased from Jackson Laboratories
and reconstituted with NOD WT bone marrow as described above, followed
by transplantation of NOD WT or Clec16a KD E14 thymic lobes under the kid-
ney capsule. Transplanted mice were challenged with cyclophosphamide to
accelerate diabetes onset.
T Cell In Vitro Assays
Purified T cells were stimulated with CD3 antibody or with the BDC2.5 mimo-
tope peptide (Judkowski et al., 2001) in the presence of irradiated T cell-
depleted splenocytes, with CD3/CD28 antibody-coated beads (Invitrogen/
Life Technologies) or with PMA (25 ng/ml) and Ionomycin (1 mg / ml). Cell pro-
liferation was measured by 3H-thymidine incorporation and analyzed with a
Microbeta plate reader (Perkin-Elmer).
Reagents, Antibodies, and Flow Cytometry
Flow cytometry measurements were performed using a FACSCantoII or LSRII
instrument (BD Biosciences). Cell sorting was performed with a FACSAriaIII
instrument (BD Biosciences). Data were analyzed with FlowJo software
(TreeStar). Fluorescently conjugated antibodies were purchased from Bio-
legend, eBioscience, and BD Biosciences. Intracellular staining was per-
formed with a FoxP3-labeling kit (eBioscience) and BrdU staining using a
flow kit (BD Biosciences).
Immunohistochemistry
Frozen sections were either stained with hematoxylin and eosin or with fluores-
cently conjugated antibodies. Slides were analyzed on a light microscope
(Olympus BX-60) or an Axioplan2 microscope (Zeiss). Image analysis was per-
formed with ImageJ64 software.
Thymic Epithelial Cell Isolation
Thymic epithelial cells were enriched using a Percoll (Fisher Scientific) density
gradient as described previously (Nedjic et al., 2008) or purified by sequential950 Immunity 42, 942–952, May 19, 2015 ª2015 Elsevier Inc.digestion with Liberase TM (Roche) and DNase (Roche) followed by CD45
depletion using a MACS Kit (Miltenyi Biotec).
Immunoblotting
SDS-PAGE was performed followed by protein transfer onto nitrocellulose
membrane and incubation with specific antibodies. Blots were analyzed using
chemiluminescence. Band density was quantified using ImageJ64 software.
Cell Lines and In Vitro Cell Assays
Generation of the MJC1 cell line and lentiviral cell transductions are described
in Supplemental Experimental Procedures. Cell starvation experiments were
performed in Earle’s Balanced Salt Solution supplemented with Rapamycin
or 3-methyladenine. Cells were treated with Bafilomycin A1 or E64d for auto-
phagic flux measurements. Thymocyte differentiation assays were performed
by stimulation of sorted DP thymocytes with CD3 and CD5 antibody or with
MJC1 cells. Generation of LC3-OVA constructs is described in Supplemental
Experimental Procedures.
Quantitative RT-PCR
RNA was isolated using the RNeasy Mini Kit (QIAGEN) or the High Pure RNA
isolation Kit (Roche) followed by cDNA synthesis using the Superscript III
cDNA synthesis Kit (Invitrogen). Primers used for RT-PCR are listed in Supple-
mental Experimental Procedures
Statistics
Data were analyzed with the Prism software (Graphpad). Diabetes frequency
comparisons were carried out using the log-rank test, except for the experi-
ment shown in Figure 1F, where Fisher’s exact test was used. All other com-
parisons were performed using a two-tailed t test, with p < 0.05 considered
significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.immuni.2015.04.011.
AUTHOR CONTRIBUTIONS
C.S., K.D.G., K.S., L.P., K.B., and A.R. designed and performed experiments
and interpreted the data. M.-J.K. generated the MJC1 cell line. T.S. contrib-
uted to data interpretation. S.K. conceived and designed the study, performed
experiments, interpreted the data, and wrote the manuscript. C.S. and K.D.G.
contributed equally to the study. All authors discussed the results and com-
mented on the manuscript.
ACKNOWLEDGMENTS
The authors thank Nicole Hain for technical assistance, Daniela Blassfeld for
help with the initial cloning and validation of lentiviral vectors, Jennifer Hollis-
ter-Lock for advice with islet purification and insulin measurements, and the
Joslin DRC (NIH Award Number P30DK036836) Flow Cytometry Core facility
for help with cell sorting. This work was supported in part by funding from
the Deutsche Forschungsgemeinschaft to the Rudolf Virchow Center (DFG
FZ82), by a Career Development Award from JDRF to S.K. (2-2010-383),
and by a Mary K. Iacocca Fellowship provided by the Iacocca Foundation to
C.S.
Received: October 23, 2014
Revised: January 16, 2015
Accepted: March 24, 2015
Published: May 12, 2015
REFERENCES
Aichinger, M., Wu, C., Nedjic, J., and Klein, L. (2013). Macroautophagy sub-
strates are loaded onto MHC class II of medullary thymic epithelial cells for
central tolerance. J. Exp. Med. 210, 287–300.
Anderson, M.S., and Bluestone, J.A. (2005). The NOD mouse: a model of im-
mune dysregulation. Annu. Rev. Immunol. 23, 447–485.
Berge, T., Leikfoss, I.S., and Harbo, H.F. (2013). From Identification to charac-
terization of the multiple sclerosis susceptibility gene CLEC16A. Int. J. Mol.
Sci. 14, 4476–4497.
Bjørkøy, G., Lamark, T., Brech, A., Outzen, H., Perander, M., Overvatn, A.,
Stenmark, H., and Johansen, T. (2005). p62/SQSTM1 forms protein aggre-
gates degraded by autophagy and has a protective effect on huntingtin-
induced cell death. J. Cell Biol. 171, 603–614.
Brazil, M.I., Weiss, S., and Stockinger, B. (1997). Excessive degradation of
intracellular protein in macrophages prevents presentation in the context of
major histocompatibility complex class II molecules. Eur. J. Immunol. 27,
1506–1514.
Cibotti, R., Punt, J.A., Dash, K.S., Sharrow, S.O., and Singer, A. (1997). Surface
molecules that drive T cell development in vitro in the absence of thymic
epithelium and in the absence of lineage-specific signals. Immunity 6,
245–255.
Daley, S.R., Hu, D.Y., and Goodnow, C.C. (2013). Helios marks strongly autor-
eactive CD4+ T cells in two major waves of thymic deletion distinguished by
induction of PD-1 or NF-kB. J. Exp. Med. 210, 269–285.
Dengjel, J., Schoor, O., Fischer, R., Reich, M., Kraus, M., Mu¨ller, M.,
Kreymborg, K., Altenberend, F., Brandenburg, J., Kalbacher, H., et al.
(2005). Autophagy promotes MHC class II presentation of peptides from intra-
cellular source proteins. Proc. Natl. Acad. Sci. USA 102, 7922–7927.
Dubois, P.C., Trynka, G., Franke, L., Hunt, K.A., Romanos, J., Curtotti, A.,
Zhernakova, A., Heap, G.A., Ada´ny, R., Aromaa, A., et al. (2010). Multiple com-
mon variants for celiac disease influencing immune gene expression. Nat.
Genet. 42, 295–302.
Fu, G., Valle´e, S., Rybakin, V., McGuire, M.V., Ampudia, J., Brockmeyer, C.,
Salek, M., Fallen, P.R., Hoerter, J.A., Munshi, A., et al. (2009). Themis controls
thymocyte selection through regulation of T cell antigen receptor-mediated
signaling. Nat. Immunol. 10, 848–856.
Gateva, V., Sandling, J.K., Hom, G., Taylor, K.E., Chung, S.A., Sun, X.,
Ortmann, W., Kosoy, R., Ferreira, R.C., Nordmark, G., et al. (2009). A large-
scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and
IL10 as risk loci for systemic lupus erythematosus. Nat. Genet. 41, 1228–1233.
Hakonarson, H., Grant, S.F., Bradfield, J.P., Marchand, L., Kim, C.E.,
Glessner, J.T., Grabs, R., Casalunovo, T., Taback, S.P., Frackelton, E.C.,
et al. (2007). A genome-wide association study identifies KIAA0350 as a
type 1 diabetes gene. Nature 448, 591–594.
Harada, M., andMakino, S. (1984). Promotion of spontaneous diabetes in non-
obese diabetes-prone mice by cyclophosphamide. Diabetologia 27, 604–606.
Hare, K.J., Jenkinson, E.J., and Anderson, G. (1999). CD69 expression dis-
criminates MHC-dependent and -independent stages of thymocyte positive
selection. J. Immunol. 162, 3978–3983.
Hirschfield, G.M., Xie, G., Lu, E., Sun, Y., Juran, B.D., Chellappa, V., Coltescu,
C., Mason, A.L., Milkiewicz, P., Myers, R.P., et al. (2012). Association of pri-
mary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE
immunomodulatory genes. Genes Immun. 13, 328–335.
Ho¨glund, P., Mintern, J., Waltzinger, C., Heath, W., Benoist, C., and Mathis, D.
(1999). Initiation of autoimmune diabetes by developmentally regulated pre-
sentation of islet cell antigens in the pancreatic lymph nodes. J. Exp. Med.
189, 331–339.
Hu, X., and Daly, M. (2012). What have we learned from six years of GWAS in
autoimmune diseases, and what is next? Curr. Opin. Immunol. 24, 571–575.
International Multiple Sclerosis Genetics Consortium (IMSGC) (2009). The ex-
panding genetic overlap betweenmultiple sclerosis and type I diabetes. Genes
Immun. 10, 11–14.
Jagielska, D., Redler, S., Brockschmidt, F.F., Herold, C., Pasternack, S.M.,
Garcia Bartels, N., Hanneken, S., Eigelshoven, S., Refke, M., Barth, S., et al.
(2012). Follow-up study of the first genome-wide association scan in alopecia
areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide
significance. J. Invest. Dermatol. 132, 2192–2197.Judkowski, V., Pinilla, C., Schroder, K., Tucker, L., Sarvetnick, N., and Wilson,
D.B. (2001). Identification of MHC class II-restricted peptide ligands, including
a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic
T cells from transgenic BDC2.5 nonobese diabetic mice. J. Immunol. 166,
908–917.
Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T.,
Kominami, E., Ohsumi, Y., and Yoshimori, T. (2000). LC3, a mammalian homo-
logue of yeast Apg8p, is localized in autophagosome membranes after pro-
cessing. EMBO J. 19, 5720–5728.
Kabeya, Y., Mizushima, N., Yamamoto, A., Oshitani-Okamoto, S., Ohsumi,
Y., and Yoshimori, T. (2004). LC3, GABARAP and GATE16 localize to auto-
phagosomal membrane depending on form-II formation. J. Cell Sci. 117,
2805–2812.
Kasai, M., Tanida, I., Ueno, T., Kominami, E., Seki, S., Ikeda, T., and Mizuochi,
T. (2009). Autophagic compartments gain access to theMHC class II compart-
ments in thymic epithelium. J. Immunol. 183, 7278–7285.
Keir, M.E., Latchman, Y.E., Freeman, G.J., and Sharpe, A.H. (2005).
Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated
positive selection of thymocytes. J. Immunol. 175, 7372–7379.
Kim, S.,Wairkar, Y.P., Daniels, R.W., and DiAntonio, A. (2010). The novel endo-
somal membrane protein Ema interacts with the class C Vps-HOPS complex
to promote endosomal maturation. J. Cell Biol. 188, 717–734.
Kim, S., Naylor, S.A., and DiAntonio, A. (2012). Drosophila Golgi membrane
protein Ema promotes autophagosomal growth and function. Proc. Natl.
Acad. Sci. USA 109, E1072–E1081.
Kissler, S., Stern, P., Takahashi, K., Hunter, K., Peterson, L.B., and Wicker,
L.S. (2006). In vivo RNA interference demonstrates a role for Nramp1 in modi-
fying susceptibility to type 1 diabetes. Nat. Genet. 38, 479–483.
Ma´rquez, A., Varade´, J., Robledo, G., Martı´nez, A., Mendoza, J.L., Taxonera,
C., Ferna´ndez-Arquero, M., Dı´az-Rubio, M., Go´mez-Garcı´a, M., Lo´pez-Nevot,
M.A., et al. (2009). Specific association of a CLEC16A/KIAA0350 polymor-
phism with NOD2/CARD15(-) Crohn’s disease patients. Eur. J. Hum. Genet.
17, 1304–1308.
Martı´nez, A., Perdigones, N., Ce´nit, M.C., Espino, L., Varade´, J., Lamas, J.R.,
Santiago, J.L., Ferna´ndez-Arquero, M., de la Calle, H., Arroyo, R., et al. (2010).
Chromosomal region 16p13: further evidence of increased predisposition to
immune diseases. Ann. Rheum. Dis. 69, 309–311.
Mero, I.L., Ban, M., Lorentzen, A˚.R., Smestad, C., Celius, E.G., Sæther, H.,
Saeedi, H., Viken, M.K., Skinningsrud, B., Undlien, D.E., et al. (2011).
Exploring the CLEC16A gene reveals a MS-associated variant with correlation
to the relative expression of CLEC16A isoforms in thymus. Genes Immun. 12,
191–198.
Mizushima, N., Sugita, H., Yoshimori, T., and Ohsumi, Y. (1998). A new protein
conjugation system in human. The counterpart of the yeast Apg12p conjuga-
tion system essential for autophagy. J. Biol. Chem. 273, 33889–33892.
Nedjic, J., Aichinger, M., Emmerich, J., Mizushima, N., and Klein, L. (2008).
Autophagy in thymic epithelium shapes the T-cell repertoire and is essential
for tolerance. Nature 455, 396–400.
Paludan, C., Schmid, D., Landthaler, M., Vockerodt, M., Kube, D., Tuschl, T.,
and Mu¨nz, C. (2005). Endogenous MHC class II processing of a viral nuclear
antigen after autophagy. Science 307, 593–596.
Plesa, G., Zheng, L., Medvec, A., Wilson, C.B., Robles-Oteiza, C., Liddy, N.,
Bennett, A.D., Gavarret, J., Vuidepot, A., Zhao, Y., et al. (2012). TCR affinity
and specificity requirements for human regulatory T-cell function. Blood
119, 3420–3430.
Schmid, D., Pypaert, M., and Mu¨nz, C. (2007). Antigen-loading compartments
for major histocompatibility complex class II molecules continuously receive
input from autophagosomes. Immunity 26, 79–92.
Skinningsrud, B., Husebye, E.S., Pearce, S.H., McDonald, D.O., Brandal, K.,
Wolff, A.B., Løva˚s, K., Egeland, T., and Undlien, D.E. (2008). Polymorphisms
in CLEC16A and CIITA at 16p13 are associated with primary adrenal insuffi-
ciency. J. Clin. Endocrinol. Metab. 93, 3310–3317.
Skinningsrud, B., Lie, B.A., Husebye, E.S., Kvien, T.K., Førre, Ø., Flatø, B.,
Stormyr, A., Joner, G., Njølstad, P.R., Egeland, T., and Undlien, D.E. (2010).Immunity 42, 942–952, May 19, 2015 ª2015 Elsevier Inc. 951
A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic
citrullinated peptide antibody negative rheumatoid arthritis. Ann. Rheum.
Dis. 69, 1471–1474.
Soleimanpour, S.A., Gupta, A., Bakay, M., Ferrari, A.M., Groff, D.N., Fadista,
J., Spruce, L.A., Kushner, J.A., Groop, L., Seeholzer, S.H., et al. (2014). The
diabetes susceptibility gene Clec16a regulates mitophagy. Cell 157, 1577–
1590.
Sukseree, S., Mildner, M., Rossiter, H., Pammer, J., Zhang, C.F.,
Watanapokasin, R., Tschachler, E., and Eckhart, L. (2012). Autophagy in the
thymic epithelium is dispensable for the development of self-tolerance in a
novel mouse model. PLoS ONE 7, e38933.
Sukseree, S., Rossiter, H., Mildner, M., Pammer, J., Buchberger, M., Gruber,
F., Watanapokasin, R., Tschachler, E., and Eckhart, L. (2013). Targeted dele-952 Immunity 42, 942–952, May 19, 2015 ª2015 Elsevier Inc.tion of Atg5 reveals differential roles of autophagy in keratin K5-expressing
epithelia. Biochem. Biophys. Res. Commun. 430, 689–694.
Swat, W., Dessing, M., von Boehmer, H., and Kisielow, P. (1993). CD69
expression during selection and maturation of CD4+8+ thymocytes. Eur. J.
Immunol. 23, 739–746.
Todd, J.A., Walker, N.M., Cooper, J.D., Smyth, D.J., Downes, K., Plagnol, V.,
Bailey, R., Nejentsev, S., Field, S.F., Payne, F., et al.; Genetics of Type 1
Diabetes in Finland; Wellcome Trust Case Control Consortium (2007).
Robust associations of four new chromosome regions from genome-wide an-
alyses of type 1 diabetes. Nat. Genet. 39, 857–864.
Wellcome Trust Case Control Consortium (2007). Genome-wide association
study of 14,000 cases of seven common diseases and 3,000 shared controls.
Nature 447, 661–678.
